Highlighting the potential of this approach, several recent translational and clinical studies beyond the field of MS used this method of delivery and were able to clear intracellular tau pathology in tauopathy mice by intranasal application of an anti-tau-antibody (144) or reduce apathy in frontotemporal dementia patients by intranasal application of oxytocin (149) (Figure 2C). Here, MAPT is linked to tauopathy.